Author Correction: SEZ6-targeting antibody−drug conjugate ABBV-706 in advanced small cell lung cancer and solid tumors: a phase 1 trial
In the version of this article initially published, ref. 10 was cited twice and has been replaced by an omitted reference (Faivre E. J. et al. Cancer Re s. https://doi.org/10.1158/1538-7445.AM2024-3148 (2024)), now cited as ref. 11 in the last paragraph of the introduction: “Preclinical studies in patient-derived xenograft models of SEZ6-positive SCLC demonstrated superior activity of ABBV-706 compared to ABBV-011 and standard-of-care chemotherapies 10 . Preliminary results from the ongoing first-in-human phase 1 trial ( NCT05599984 ) to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity and antitumor activity of ABBV-706 in patients with R/R solid tumors (defined as those patients whose disease had progressed on or after treatment with standard of care), including patients with R/R SCLC, demonstrated that ABBV-706 monotherapy had a manageable safety profile and promising antitumor activity, with a confirmed ORR of 43.8% (60.9% in patients with R/R SCLC) 11 .” The reference has been updated in the HTML and PDF version of the article.
Authors
- Jair Bar (ORCID: https://orcid.org/0000-0002-1224-3646)
- Darius Meiman (ORCID: https://orcid.org/0000-0002-1005-9175)
- Kyriakos P. Papadopoulos (ORCID: https://orcid.org/0000-0002-0667-2620)
- Ji‐Youn Han (ORCID: https://orcid.org/0000-0001-5033-0006)
- Noura J. Choudhury (ORCID: https://orcid.org/0000-0002-5980-4973)
- Anne C. Chiang (ORCID: https://orcid.org/0000-0002-2111-4694)
- Myung‐Ju Ahn (ORCID: https://orcid.org/0000-0002-5740-9654)
- Hiroshi Yokouchi (ORCID: https://orcid.org/0000-0001-5964-0051)
- Randy Robinson (ORCID: https://orcid.org/0000-0002-9503-1111)
- Luis Paz‐Ares (ORCID: https://orcid.org/0000-0002-1947-3364)
- Pooja Hingorani (ORCID: https://orcid.org/0000-0002-4772-7456)
- Cristiano Ferlini (ORCID: https://orcid.org/0000-0003-3886-9134)
- Byoung Chul Cho (ORCID: https://orcid.org/0000-0002-5562-270X)
- Lauren A. Byers (ORCID: https://orcid.org/0000-0002-0780-2677)
- Tae Min Kim (ORCID: https://orcid.org/0000-0001-6145-4426)
- Young‐Chul Kim (ORCID: https://orcid.org/0000-0001-7019-7687)
- M. Vieito
- Sreenivasa Chandana
- Oluwadamilola Ogunyankin
- Wijith Munasinghe
- Nadine Jahchan
- Muhammad Furqan
- Wallace Akerley
- Tammy Palenski
- Joo-Hang Kim
- Guillermo Rivell
- Alissa J. Cooper
- Frederick J. Kohlhapp
- Afshin Dowlati
- Song Wang (ORCID: https://orcid.org/0009-0004-7267-5848)
- Daniel Morgensztern
Institutions
- University of Iowa (US)
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Tel Aviv University (IL)
- Yonsei University (KR)
- Washington University in St. Louis (US)
- University of Utah (US)
- Sheba Medical Center (IL)
- Huntsman Cancer Institute (US)
- Seoul National University Hospital (KR)
- AbbVie (United States) (US)
- Yale University (US)
- University of Chicago (US)
- Hospital Universitario 12 De Octubre (ES)
- National Hospital Organization Hokkaido Medical Center (JP)
- South Texas Accelerated Research Therapeutics (US)
- University Hospitals Seidman Cancer Center (US)
- National Cancer Center (KR)
- Vall d'Hebron Hospital Universitari (ES)
- CHA University Bundang Medical Center (KR)
- Chonnam National University Hwasun Hospital (KR)
- CHA University (KR)
- Hanyang University Medical Center (KR)
- Start Treatment & Recovery Centers (US)
- Sapporo National Hospital (JP)
- Vall d'Hebron Institute of Oncology (ES)
- University of Iowa Holden Comprehensive Cancer Center
- Case Western Reserve University (US)
Publication Details
- Journal
- Nature Medicine
- Published
- 2026-06-29
- DOI
- https://doi.org/10.1038/s41591-026-04544-x
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00